$19.91
+0.77 (+4.02%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where SIBN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
7 interventional · 6 observational · 2 with posted results
Held by 10 tracked-famous managers (Point72 Asset Management, L.P., First Eagle Investment Management, LLC, MARSHALL WACE, LLP, MILLENNIUM MANAGEMENT LLC, AQR CAPITAL MANAGEMENT LLC, +5 more) · FINRA short interest 10.9 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 3 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Innovative Spinopelvic Solutions With Real-World EvidenceNCT06706908observationalChange in patient reported outcomes | — | Active, not recruiting | Other: Health questionnaires | Sacroiliac Joint Dysfunction, Sacroiliac Joint Pain | 1,000 | Dec 2034 | ≤ 3,055 d | 2026-04-24 |
| Posterior-Inferior Intra-articular Cortical Piercing Titanium Implant for Sacroiliac Joint Fusion: Evaluation of Safety and Effectiveness OutcomesNCT07565545observationalComposite endpoint of safety and performance | — | Not yet recruiting | Device: iFuse INTRA Ti Implant System | Sacro Iliac Joint Pain, Sacro-iliac Joints, Sacroiliac Disorder, Sacroiliac Joint Dysfunction, Sacroiliac Joint Disruption, Degenerative Sacroiliitis | 120 | Mar 2028 | ≤ 589 d | 2026-06-22 |
| Real World Evidence of SI-BONE's iFuse TORQ TNT Advancing Treatment of Pelvic Ring FracturesNCT07530497observationalComposite Measure | — | Recruiting | Device: iFuse TORQ TNT Implant System | Fracture; Pelvic, Insufficiency Fractures, Fragility Fracture, Sacroiliac; Fusion, Sacroiliac Joint Disruption, Sacroiliac Joint Dysfunction | 120 | Feb 2028 | ≤ 558 d | 2026-08-07 |
| Pelvic Fixation and Fusion During Multilevel Spinal SurgeryNCT05640908observationalPostoperative incidence of serious adverse events probably or definitely related to GRANITE | — | Active, not recruiting | Device: iFuse Bedrock Granite Implant System | Spinal Fusion, Deformity of Spine | 200 | Nov 2027 | ≤ 467 d | 2026-01-23 |
| iFuse TORQ for the Treatment of Sacroiliac Joint DysfunctionNCT05870488Change in SI joint pain measured by numerical rating scale (NRS)Open-label · Treatment | Phase 4 | Active, not recruiting | Device: Use of iFuse TORQ | Sacroiliac Joint Dysfunction, Sacroiliac; Fusion, Sacroiliac Disorder, Sacroiliac Joint Pain | 110 | 2025-04-23actual | — | 2026-08-06 |
| SI Joint Stabilization in Long Fusion to the PelvisNCT04062630Proportion with S2AI screw abnormality on CT scanRandomized · Single-masked · Treatment | Not applicable | Completed | Device: iFuse 3-D in Bedrock Configuration · Procedure: Multilevel Lumbar Fusion surgery | Sacroiliac Joint Disruption, Scoliosis Lumbar Region | 213 | 2024-12-17actual | — | 2025-02-18 |
| Study of Bone Growth in the Sacroiliac Joint After Minimally Invasive Surgery With Titanium ImplantsNCT03122899Primary Radiographic Outcome: Bone adherenceRandomized · Open-label · Treatment | Not applicable | Completed | Device: SIJ fusion with iFuse-3D | Sacroiliac Dysfunction | 51 | 2024-06-19actual | — | 2025-06-05 |
| Sacral Fracture Fusion/Fixation for Rapid RehabilitationNCT05426356Time following treatment initiation to reach a 2-point improvement in mobility from baseline as measured using self-rated Modified Functional Mobility scale (MFMS).Randomized · Open-label · Treatment | Not applicable | Terminatedsponsor's stated reason: Enrollment difficulties | Device: Surgical Intervention · Other: Non-Surgical Management | Fracture;Pelvis, Sacral Fracture, Sacroiliac; Fusion, Fragility Fracture, Insufficiency Fractures, Osteoporosis | 28 | 2024-06-15actual | — | 2024-10-24 |
| LOIS: Long-Term Follow-Up in INSITE/SIFINCT02270203observationalSubject Success | — | Completed | Radiation: Pelvic CT at 5 years post-op | Degenerative Sacroilitis, Sacroiliac Joint Disruption | 103 | Jul 2019actual | — | 2019-08-06 |
| iFuse Implant System® Minimally Invasive ArthrodesisNCT01741025The change in lower back pain as rated by the study subject using a 0-100 visual analog scale (VAS) at 6 months after initiation of treatmentRandomized · Open-label · Treatment | Not applicable | Completed | Device: iFuse Implant System · Other: Conservative Management | Sacroiliac Joint Pain | 103 | 2015-12-15actual | — | 2017-10-03 |
| Investigation of Sacroiliac Fusion Treatment (INSITE)NCT01681004results2017-08-25Subject SuccessRandomized · Open-label · Treatment | Not applicable | Completed | Device: iFuse Implant System · Other: Non-surgical management | Degenerative Sacroiliitis, Sacroiliac Joint Disruption | 159 | Feb 2015actual | — | 2017-08-25 |
| Sacroiliac Joint Fusion With iFuse Implant System (SIFI)NCT01640353results2017-03-24observationalSubject Success | — | Completed | — | Degenerative Sacroiliitis, Sacroiliac Joint Disruption | 194 | Jan 2015actual | — | 2017-03-24 |
| Validity and Reliability of Diagnostic Findings of SI Joint BlockingNCT01874236Numeric Rating ScaleRandomized · Double-masked · Diagnostic | Phase 4 | Terminatedsponsor's stated reason: Data could not be interpreted. Re-design efforts failed. | Drug: 0.75% bupivacaine, .75% bupivacaine, .75% bupivacaine | SI Joint Pain | 28 | 2014-09-30actual | — | 2019-09-24 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19